Search
  • Within this site
AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

Non Insulin Based Type II Diabetes Therapy


Technology Benefits

The researchers have developed novel compositions that have been demonstrated to be safe and effective in an animal model of diabetes (rodent) Can be taken orally unlike insulin, eliminating the need for painful injections As a therapy restoring the body's ability to regulate blood glucose on its own, it will lead to better real time glucose management, alleviating the deleterious health effects of hyperglycemia A metabolic precursor to this molecule has been used for five decades to treat unrelated conditions and has proven itself to be safe and well tolerated by patients Has the potential to eliminate the adverse side effects, like hypoglycemia and weight gain, of most current diabetes therapies


Technology Application

A new, non-insulin based therapy for type II diabetes to aid the body's native insulin response to blood glucose levels; may be used independently or in conjunction with other therapies Allows for the use of a radiolabeled variant of the inhibitor to target beta cells in the pancreas to quantify progression of disease based on the degree of radioactive labeling


Detailed Technology Description

One of the factors contributing to type II diabetes is impaired beta cell function and loss of response to hyperglycemic stimulus. This technology is a novel inhibitor of an ATP dependent transporter molecule expressed in beta cells, which is respons...


Country/Region

USA

For more information, please click Here
Business of IP Asia Forum
Desktop View